-
-
-
-
-
-
-
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
-
-
-
-
-
-
-
Opus Genetics (IRD) Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
-
-
-
-
-
-
-
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

